RA'ANANA, Israel, Dec. 10,
2024 /PRNewswire/ -- Inspira Technologies Oxy
B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies"
or the "Company"), a groundbreaking life support
technology company, revealed the expansion of its HYLA blood sensor
technology ("HYLA") into an immediate personalized Blood Lab Test,
aimed at performing real-time patient blood work for the rapid
detection in minutes of the potential development of an underlying
life-threatening medical condition.
The HYLA business model is designed to replace the need for
nurses to take intermittent physical blood samples from patients
undergoing extracorporeal procedures by providing patient blood
work with pre-determined setup options, or alternatively,
supporting physical immediate intermittent blood work testing and
analysis. The HYLA is expected to be used near a patient's bed in
ER's, ICU's, Medical Units and in operating rooms, with the
potential to replace expensive equipment, eliminate the need for
blood cartridges and dependency on central labs and reduce the
burden on hospital staff. The HYLA technology could also
potentially reduce countless tests performed each year where
valuable time is often lost between the time of ordering a blood
test and when test results are received, which can impact patient
treatment and outcomes.
The HYLA is undergoing clinical evaluations in Sheba Hospital
(Ranked 9th in the world by Newsweek™ magazine) in
patients undergoing open-heart procedures, in preparation of the
Company's planned U.S. Food and Drug Administration ("FDA")
submission of the first configuration of the HYLA in 2025.
"Our plans to use HYLA to perform blood work without the need to
take physical blood samples is part of a broader business
strategy," said Dagi Ben-Noon, CEO of Inspira Technologies.
"The core technologies of the INSPIRA ART are progressing, with the
Company currently performing a clinical evaluation of the HYLA
blood technology at Sheba hospital, with results expected to be
revealed in the near future."
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the life support and respiratory treatment arena. The Company
has developed a breakthrough Augmented Respiration Technology
(INSPIRA™ ART), a groundbreaking device poised to revolutionize
the $19 billion mechanical ventilation market. With 20
million intensive care unit patients with acute respiratory failure
each year, many of whom rely on mechanical ventilators, the INSPIRA
ART offers a potential alternative by elevating and stabilizing
decreasing oxygen saturation levels in minutes without a
ventilators, with patient being awake during treatment. The INSPIRA
ART is being equipped with the HYLA™ blood sensor technology, a
real-time continuous blood monitoring technology, aiming to alert
physicians of changes in a patient's condition without the need for
intermittent actual blood samples, and potentially supporting
physicians in making informed decisions.
The Company's INSPIRA™ ART100 system has
obtained FDA 510(k) clearance for use in Cardiopulmonary Bypass
procedures, along with the Israeli AMAR certification for both
Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass
procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX orbiting Oxygen
Delivery System and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans and have not been approved by any regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com
Forward-Looking Statements
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the potential use and
design of its products and technologies, the expected timing of its
FDA submission and the potential size of its target market and that
its development of innovative life support technology could disrupt
the $19 billion mechanical
ventilation market. These forward-looking statements and their
implications are based solely on the current expectations of the
Company's management and are subject to a number of factors and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Except as
otherwise required by law, the Company undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities
and Exchange Commission (the "SEC"), which is available on the
SEC's website, www.sec.gov.
Contact:
For more information, contact:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-expands-hyla-blood-sensor-technology-into-personalized-blood-lab-testing-for-rapid-detection-of-serious-medical-conditions-302327457.html
SOURCE Inspira Technologies
